Erasca to Present at Upcoming Conferences in February
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Erasca (Nasdaq: ERAS) announced management will present and hold one-on-one investor meetings at two February 2026 conferences: Guggenheim Emerging Outlook: Biotech Summit (Feb 11-12) and Oppenheimer 36th Annual Healthcare Life Sciences Conference (Feb 25-26).
Fireside chat times: Feb 12 at 1:00 PM ET (Guggenheim) and Feb 26 at 11:20 AM ET (Oppenheimer). Live audio webcasts and archived replays will be available at Erasca.com/events for 30 days following each webcast.
Details
News Market Reaction – ERAS
On Feb 5, the day this news came out, ERAS closed 5.69% above the previous close.
Data tracked by StockTitan Argus for the Feb 5 session.
Key Figures
- Guggenheim Summit dates
- February 11-12, 2026
- Guggenheim Emerging Outlook: Biotech Summit 2026
- Guggenheim fireside time
- February 12, 1:00 pm ET
- Guggenheim Biotech Summit 2026 fireside chat
- Oppenheimer conf dates
- February 25-26, 2026
- Oppenheimer 36th Annual Healthcare Life Sciences Conference
- Oppenheimer fireside time
- February 26, 11:20 am ET
- Oppenheimer conference fireside chat
- Webcast replay window
- 30 days
- Archived conference webcasts at Erasca.com/events
Historical Context
-
Closed upsized common stock offering at $10.00 for $258.8M gross.
-
Priced upsized 22,500,000-share offering at $10.00 per share.
-
Proposed $150.0M common stock offering under effective shelf.
-
Reported early Phase 1 responses for ERAS-0015 with favorable safety profile.
-
Announced J.P. Morgan Healthcare Conference presentation with webcast and replay.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN DIEGO, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced that management will participate in the following investor conferences in February 2026 and will also participate in one-on-one investor meetings at each of these conferences.
Guggenheim Emerging Outlook: Biotech Summit 2026 (February 11-12, 2026)
Location: New York, NY
Format: Fireside Chat
Date and Time: Thursday, February 12, 1:00 pm Eastern Time
Oppenheimer 36th Annual Healthcare Life Sciences Conference (February 25-26, 2026)
Location: Virtual
Format: Fireside Chat
Date and Time: Thursday, February 26, 11:20 am Eastern Time
A live audio webcast of the events will be available online at Erasca.com/events. An archived replay of the events will be available for 30 days following the webcast at Erasca.com/events.
About Erasca
At Erasca, our name is our mission: To erase cancer. We are a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Our company was co-founded by leading pioneers in precision oncology and RAS targeting to create novel therapies and combination regimens designed to comprehensively shut down the RAS/MAPK pathway for the treatment of patients with cancer. We believe our team’s capabilities and experience, further guided by our scientific advisory board which includes the world’s leading experts in the RAS/MAPK pathway, uniquely position us to achieve our bold mission of erasing cancer.
Contact:
Joyce Allaire
LifeSci Advisors, LLC
jallaire@lifesciadvisors.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.